BLACKSBURG, Va., April 30 -- Virginia Polytechnic Institute and State University issued the following news release:
A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in preclinical models.
A new study in the journalTheranostics,led by senior author Yassine Sassi, assistant professor with the Fralin Biomedical Research Institute, found that simultaneously inhibiting two proteins - ID1 and ID3 - significantly reduced lung scarring and improved lung function across multiple experimental systems.
IPF is a progressive disease in which scar tissue builds up in the lungs, making it increasingly difficult to ...